The history of cyclosporin A (Sandimmune®) revisited: Another point of view
- 1 January 1996
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 52 (1) , 5-13
- https://doi.org/10.1007/bf01922409
Abstract
The immunosuppressant cyclosporin A (Sandimmune®) has become the first line treatment for preventing rejection of transplanted organs and for certain, autoimmune diseases. The discovery of that drug and its preclinical development are described, and it is shown that most earlier accounts of the history of this compound are, in important respects, incorrect and misleading.Keywords
This publication has 58 references indexed in Scilit:
- Enhanced toxicity of the immunosuppressant ovalicin upon application to the skinCellular and Molecular Life Sciences, 1988
- Inhibition of human lymphocyte transformation by the macrocyclic trichothecenes roridin A and verrucarin AToxicology Letters, 1988
- Antimalarial activity of cyclosporin AInflammation Research, 1981
- Antischistosomal effects of cyclosporin AInflammation Research, 1981
- CYCLOSPORIN A FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN MANThe Lancet, 1978
- Cyclosporin A, ein immunsuppressiv wirksamer Peptidmetabolit aus Trichoderma polysporum (LINK ex PERS.) RifaiHelvetica Chimica Acta, 1976
- Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptidePublished by Elsevier ,1974
- Effect of the immunosuppressive agent ovalicin on the kinetics of antibody formationInflammation Research, 1970
- 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of actionPublished by Elsevier ,1970
- The cytochalasins, a new class of biologically active mould metabolitesChemical Communications (London), 1967